ID   KPCZ_HUMAN              Reviewed;         592 AA.
AC   Q05513; A8K4N0; A8MU64; B7Z2J7; E9PCW2; Q15207; Q5SYT5; Q969S4;
DT   01-FEB-1994, integrated into UniProtKB/Swiss-Prot.
DT   21-JUN-2005, sequence version 4.
DT   10-MAY-2017, entry version 200.
DE   RecName: Full=Protein kinase C zeta type;
DE            EC=2.7.11.13;
DE   AltName: Full=nPKC-zeta;
GN   Name=PRKCZ; Synonyms=PKC2;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Frontal cortex;
RX   PubMed=8224878; DOI=10.1016/0378-1119(93)90213-M;
RA   Barbee J.L., Loomis C.R., Deutscher S.L., Burns D.J.;
RT   "The cDNA sequence encoding human protein kinase C-zeta.";
RL   Gene 132:305-306(1993).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RA   Kalnine N., Chen X., Rolfs A., Halleck A., Hines L., Eisenstein S.,
RA   Koundinya M., Raphael J., Moreira D., Kelley T., LaBaer J., Lin Y.,
RA   Phelan M., Farmer A.;
RT   "Cloning of human full-length CDSs in BD Creator(TM) system donor
RT   vector.";
RL   Submitted (MAY-2003) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3).
RC   TISSUE=Brain, and Teratocarcinoma;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16710414; DOI=10.1038/nature04727;
RA   Gregory S.G., Barlow K.F., McLay K.E., Kaul R., Swarbreck D.,
RA   Dunham A., Scott C.E., Howe K.L., Woodfine K., Spencer C.C.A.,
RA   Jones M.C., Gillson C., Searle S., Zhou Y., Kokocinski F.,
RA   McDonald L., Evans R., Phillips K., Atkinson A., Cooper R., Jones C.,
RA   Hall R.E., Andrews T.D., Lloyd C., Ainscough R., Almeida J.P.,
RA   Ambrose K.D., Anderson F., Andrew R.W., Ashwell R.I.S., Aubin K.,
RA   Babbage A.K., Bagguley C.L., Bailey J., Beasley H., Bethel G.,
RA   Bird C.P., Bray-Allen S., Brown J.Y., Brown A.J., Buckley D.,
RA   Burton J., Bye J., Carder C., Chapman J.C., Clark S.Y., Clarke G.,
RA   Clee C., Cobley V., Collier R.E., Corby N., Coville G.J., Davies J.,
RA   Deadman R., Dunn M., Earthrowl M., Ellington A.G., Errington H.,
RA   Frankish A., Frankland J., French L., Garner P., Garnett J., Gay L.,
RA   Ghori M.R.J., Gibson R., Gilby L.M., Gillett W., Glithero R.J.,
RA   Grafham D.V., Griffiths C., Griffiths-Jones S., Grocock R.,
RA   Hammond S., Harrison E.S.I., Hart E., Haugen E., Heath P.D.,
RA   Holmes S., Holt K., Howden P.J., Hunt A.R., Hunt S.E., Hunter G.,
RA   Isherwood J., James R., Johnson C., Johnson D., Joy A., Kay M.,
RA   Kershaw J.K., Kibukawa M., Kimberley A.M., King A., Knights A.J.,
RA   Lad H., Laird G., Lawlor S., Leongamornlert D.A., Lloyd D.M.,
RA   Loveland J., Lovell J., Lush M.J., Lyne R., Martin S.,
RA   Mashreghi-Mohammadi M., Matthews L., Matthews N.S.W., McLaren S.,
RA   Milne S., Mistry S., Moore M.J.F., Nickerson T., O'Dell C.N.,
RA   Oliver K., Palmeiri A., Palmer S.A., Parker A., Patel D., Pearce A.V.,
RA   Peck A.I., Pelan S., Phelps K., Phillimore B.J., Plumb R., Rajan J.,
RA   Raymond C., Rouse G., Saenphimmachak C., Sehra H.K., Sheridan E.,
RA   Shownkeen R., Sims S., Skuce C.D., Smith M., Steward C.,
RA   Subramanian S., Sycamore N., Tracey A., Tromans A., Van Helmond Z.,
RA   Wall M., Wallis J.M., White S., Whitehead S.L., Wilkinson J.E.,
RA   Willey D.L., Williams H., Wilming L., Wray P.W., Wu Z., Coulson A.,
RA   Vaudin M., Sulston J.E., Durbin R.M., Hubbard T., Wooster R.,
RA   Dunham I., Carter N.P., McVean G., Ross M.T., Harrow J., Olson M.V.,
RA   Beck S., Rogers J., Bentley D.R.;
RT   "The DNA sequence and biological annotation of human chromosome 1.";
RL   Nature 441:315-321(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Colon, and Ovary;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 7-592.
RC   TISSUE=Hippocampus;
RX   PubMed=8375396; DOI=10.1111/j.1432-1033.1993.tb18179.x;
RA   Kochs G., Hummel R., Meyer D., Hug H., Marme D., Sarre T.F.;
RT   "Activation and substrate specificity of the human protein kinase C
RT   alpha and zeta isoenzymes.";
RL   Eur. J. Biochem. 216:597-606(1993).
RN   [7]
RP   SUBCELLULAR LOCATION.
RX   PubMed=7597083; DOI=10.1073/pnas.92.13.6072;
RA   Stuart R.O., Nigam S.K.;
RT   "Regulated assembly of tight junctions by protein kinase C.";
RL   Proc. Natl. Acad. Sci. U.S.A. 92:6072-6076(1995).
RN   [8]
RP   FUNCTION IN ACTIVATION OF MAP2K1/MEK1 AND MAPK1/ERK2.
RX   PubMed=9447975; DOI=10.1128/MCB.18.2.790;
RA   Schoenwasser D.C., Marais R.M., Marshall C.J., Parker P.J.;
RT   "Activation of the mitogen-activated protein kinase/extracellular
RT   signal-regulated kinase pathway by conventional, novel, and atypical
RT   protein kinase C isotypes.";
RL   Mol. Cell. Biol. 18:790-798(1998).
RN   [9]
RP   INTERACTION WITH SQSTM1, AND SUBCELLULAR LOCATION.
RX   PubMed=9566925; DOI=10.1128/MCB.18.5.3069;
RA   Sanchez P., De Carcer G., Sandoval I.V., Moscat J., Diaz-Meco M.T.;
RT   "Localization of atypical protein kinase C isoforms into lysosome-
RT   targeted endosomes through interaction with p62.";
RL   Mol. Cell. Biol. 18:3069-3080(1998).
RN   [10]
RP   PHOSPHORYLATION AT THR-410 BY PDPK1.
RX   PubMed=9768361; DOI=10.1016/S0960-9822(98)70444-0;
RA   Chou M.M., Hou W., Johnson J., Graham L.K., Lee M.H., Chen C.S.,
RA   Newton A.C., Schaffhausen B.S., Toker A.;
RT   "Regulation of protein kinase C zeta by PI 3-kinase and PDK-1.";
RL   Curr. Biol. 8:1069-1077(1998).
RN   [11]
RP   INTERACTION WITH SQSTM1 AND IKBKB.
RX   PubMed=10356400; DOI=10.1093/emboj/18.11.3044;
RA   Sanz L., Sanchez P., Lallena M.-J., Diaz-Meco M.T., Moscat J.;
RT   "The interaction of p62 with RIP links the atypical PKCs to NF-kappaB
RT   activation.";
RL   EMBO J. 18:3044-3053(1999).
RN   [12]
RP   FUNCTION IN ACTIVATION OF MAPK1/ERK2.
RX   PubMed=11035106; DOI=10.4049/jimmunol.165.8.4632;
RA   Monick M.M., Carter A.B., Flaherty D.M., Peterson M.W.,
RA   Hunninghake G.W.;
RT   "Protein kinase C zeta plays a central role in activation of the
RT   p42/44 mitogen-activated protein kinase by endotoxin in alveolar
RT   macrophages.";
RL   J. Immunol. 165:4632-4639(2000).
RN   [13]
RP   INTERACTION WITH PARD6A; PARD6B AND PARD6G.
RC   TISSUE=Neuroblastoma;
RX   PubMed=11260256; DOI=10.1046/j.1365-2443.2001.00404.x;
RA   Noda Y., Takeya R., Ohno S., Naito S., Ito T., Sumimoto H.;
RT   "Human homologues of the Caenorhabditis elegans cell polarity protein
RT   PAR6 as an adaptor that links the small GTPases Rac and Cdc42 to
RT   atypical protein kinase C.";
RL   Genes Cells 6:107-119(2001).
RN   [14]
RP   INTERACTION WITH PDPK1, AND PHOSPHORYLATION.
RX   PubMed=11781095; DOI=10.1021/bi010719z;
RA   Hodgkinson C.P., Sale G.J.;
RT   "Regulation of both PDK1 and the phosphorylation of PKC-zeta and
RT   -delta by a C-terminal PRK2 fragment.";
RL   Biochemistry 41:561-569(2002).
RN   [15]
RP   FUNCTION IN ACTIVATION OF AKT3.
RX   PubMed=12162751; DOI=10.1021/bi026065r;
RA   Hodgkinson C.P., Sale E.M., Sale G.J.;
RT   "Characterization of PDK2 activity against protein kinase B gamma.";
RL   Biochemistry 41:10351-10359(2002).
RN   [16]
RP   INTERACTION WITH SQSTM1 AND PAWR.
RX   PubMed=11755531; DOI=10.1016/S0014-5793(01)03224-0;
RA   Chang S., Kim J.H., Shin J.;
RT   "p62 forms a ternary complex with PKCzeta and PAR-4 and antagonizes
RT   PAR-4-induced PKCzeta inhibition.";
RL   FEBS Lett. 510:57-61(2002).
RN   [17]
RP   INTERACTION WITH PARD3.
RX   PubMed=12234671; DOI=10.1016/S0378-1119(02)00681-9;
RA   Gao L., Macara I.G., Joberty G.;
RT   "Multiple splice variants of Par3 and of a novel related gene, Par3L,
RT   produce proteins with different binding properties.";
RL   Gene 294:99-107(2002).
RN   [18]
RP   INTERACTION WITH ADAP1.
RX   PubMed=12893243; DOI=10.1016/S0006-291X(03)01187-2;
RA   Zemlickova E., Dubois T., Kerai P., Clokie S., Cronshaw A.D.,
RA   Wakefield R.I.D., Johannes F.-J., Aitken A.;
RT   "Centaurin-alpha(1) associates with and is phosphorylated by isoforms
RT   of protein kinase C.";
RL   Biochem. Biophys. Res. Commun. 307:459-465(2003).
RN   [19]
RP   INTERACTION WITH SQSTM1 AND PARD6B, DOMAIN, AND MUTAGENESIS OF LYS-19;
RP   ASP-62 AND ASP-66.
RX   PubMed=12887891; DOI=10.1016/S1097-2765(03)00246-6;
RA   Wilson M.I., Gill D.J., Perisic O., Quinn M.T., Williams R.L.;
RT   "PB1 domain-mediated heterodimerization in NADPH oxidase and signaling
RT   complexes of atypical protein kinase C with Par6 and p62.";
RL   Mol. Cell 12:39-50(2003).
RN   [20]
RP   FUNCTION IN PHOSPHORYLATION OF MARK2 AND MARK3.
RX   PubMed=15084291; DOI=10.1016/j.cub.2004.04.007;
RA   Hurov J.B., Watkins J.L., Piwnica-Worms H.;
RT   "Atypical PKC phosphorylates PAR-1 kinases to regulate localization
RT   and activity.";
RL   Curr. Biol. 14:736-741(2004).
RN   [21]
RP   FUNCTION IN PHOSPHORYLATION OF MARK2.
RX   PubMed=15324659; DOI=10.1016/j.cub.2004.08.021;
RA   Suzuki A., Hirata M., Kamimura K., Maniwa R., Yamanaka T., Mizuno K.,
RA   Kishikawa M., Hirose H., Amano Y., Izumi N., Miwa Y., Ohno S.;
RT   "aPKC acts upstream of PAR-1b in both the establishment and
RT   maintenance of mammalian epithelial polarity.";
RL   Curr. Biol. 14:1425-1435(2004).
RN   [22]
RP   PHOSPHORYLATION AT THR-410 BY PI3K.
RX   PubMed=15314172; DOI=10.1128/MCB.24.17.7643-7653.2004;
RA   Castoria G., Migliaccio A., Di Domenico M., Lombardi M., de Falco A.,
RA   Varricchio L., Bilancio A., Barone M.V., Auricchio F.;
RT   "Role of atypical protein kinase C in estradiol-triggered G1/S
RT   progression of MCF-7 cells.";
RL   Mol. Cell. Biol. 24:7643-7653(2004).
RN   [23]
RP   INTERACTION WITH WDFY2.
RX   PubMed=16792529; DOI=10.1042/BJ20060511;
RA   Fritzius T., Burkard G., Haas E., Heinrich J., Schweneker M.,
RA   Bosse M., Zimmermann S., Frey A.D., Caelers A., Bachmann A.S.,
RA   Moelling K.;
RT   "A WD-FYVE protein binds to the kinases Akt and PKCzeta/lambda.";
RL   Biochem. J. 399:9-20(2006).
RN   [24]
RP   FUNCTION, INTERACTION WITH VAMP2, COMPLEX FORMATION WITH VAMP2 AND
RP   WDFY2, AND SUBCELLULAR LOCATION.
RX   PubMed=17313651; DOI=10.1111/j.1742-4658.2007.05702.x;
RA   Fritzius T., Frey A.D., Schweneker M., Mayer D., Moelling K.;
RT   "WD-repeat-propeller-FYVE protein, ProF, binds VAMP2 and protein
RT   kinase Czeta.";
RL   FEBS J. 274:1552-1566(2007).
RN   [25]
RP   INTERACTION WITH WWC1 AND DDR1.
RX   PubMed=18190796; DOI=10.1016/j.bbamcr.2007.12.007;
RA   Hilton H.N., Stanford P.M., Harris J., Oakes S.R., Kaplan W.,
RA   Daly R.J., Ormandy C.J.;
RT   "KIBRA interacts with discoidin domain receptor 1 to modulate
RT   collagen-induced signalling.";
RL   Biochim. Biophys. Acta 1783:383-393(2008).
RN   [26]
RP   FUNCTION IN PHOSPHORYLATION OF STK11.
RX   PubMed=18321849; DOI=10.1074/jbc.M708208200;
RA   Song P., Xie Z., Wu Y., Xu J., Dong Y., Zou M.H.;
RT   "Protein kinase Czeta-dependent LKB1 serine 428 phosphorylation
RT   increases LKB1 nucleus export and apoptosis in endothelial cells.";
RL   J. Biol. Chem. 283:12446-12455(2008).
RN   [27]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of
RT   the kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [28]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-560, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [29]
RP   SUBCELLULAR LOCATION, SUBUNIT, AND PHOSPHORYLATION AT THR-410.
RX   PubMed=20332120; DOI=10.1242/jcs.059329;
RA   Lampugnani M.G., Orsenigo F., Rudini N., Maddaluno L., Boulday G.,
RA   Chapon F., Dejana E.;
RT   "CCM1 regulates vascular-lumen organization by inducing endothelial
RT   polarity.";
RL   J. Cell Sci. 123:1073-1080(2010).
RN   [30]
RP   REVIEW ON FUNCTION.
RX   PubMed=12761192; DOI=10.1093/jb/mvg017;
RA   Hirai T., Chida K.;
RT   "Protein kinase Czeta (PKCzeta): activation mechanisms and cellular
RT   functions.";
RL   J. Biochem. 133:1-7(2003).
RN   [31]
RP   REVIEW ON FUNCTION.
RX   PubMed=16903823; DOI=10.1134/S0006297906070017;
RA   Liu L.Z., He A.B., Liu X.J., Li Y., Chang Y.S., Fang F.D.;
RT   "Protein kinase Czeta and glucose uptake.";
RL   Biochemistry (Mosc.) 71:701-706(2006).
RN   [32]
RP   REVIEW ON FUNCTION.
RX   PubMed=16322752; DOI=10.1038/sj.cdd.4401823;
RA   Moscat J., Rennert P., Diaz-Meco M.T.;
RT   "PKCzeta at the crossroad of NF-kappaB and Jak1/Stat6 signaling
RT   pathways.";
RL   Cell Death Differ. 13:702-711(2006).
RN   [33]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [34]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-560, AND IDENTIFICATION
RP   BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D.,
RA   Wang L., Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human
RT   liver phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [35]
RP   VARIANT [LARGE SCALE ANALYSIS] PHE-514.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [36]
RP   VARIANTS [LARGE SCALE ANALYSIS] HIS-84 AND CYS-519.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Calcium- and diacylglycerol-independent
CC       serine/threonine-protein kinase that functions in
CC       phosphatidylinositol 3-kinase (PI3K) pathway and mitogen-activated
CC       protein (MAP) kinase cascade, and is involved in NF-kappa-B
CC       activation, mitogenic signaling, cell proliferation, cell
CC       polarity, inflammatory response and maintenance of long-term
CC       potentiation (LTP). Upon lipopolysaccharide (LPS) treatment in
CC       macrophages, or following mitogenic stimuli, functions downstream
CC       of PI3K to activate MAP2K1/MEK1-MAPK1/ERK2 signaling cascade
CC       independently of RAF1 activation. Required for insulin-dependent
CC       activation of AKT3, but may function as an adapter rather than a
CC       direct activator. Upon insulin treatment may act as a downstream
CC       effector of PI3K and contribute to the activation of translocation
CC       of the glucose transporter SLC2A4/GLUT4 and subsequent glucose
CC       transport in adipocytes. In EGF-induced cells, binds and activates
CC       MAP2K5/MEK5-MAPK7/ERK5 independently of its kinase activity and
CC       can activate JUN promoter through MEF2C. Through binding with
CC       SQSTM1/p62, functions in interleukin-1 signaling and activation of
CC       NF-kappa-B with the specific adapters RIPK1 and TRAF6.
CC       Participates in TNF-dependent transactivation of NF-kappa-B by
CC       phosphorylating and activating IKBKB kinase, which in turn leads
CC       to the degradation of NF-kappa-B inhibitors. In migrating
CC       astrocytes, forms a cytoplasmic complex with PARD6A and is
CC       recruited by CDC42 to function in the establishment of cell
CC       polarity along with the microtubule motor and dynein. In
CC       association with FEZ1, stimulates neuronal differentiation in PC12
CC       cells. In the inflammatory response, is required for the T-helper
CC       2 (Th2) differentiation process, including interleukin production,
CC       efficient activation of JAK1 and the subsequent phosphorylation
CC       and nuclear translocation of STAT6. May be involved in development
CC       of allergic airway inflammation (asthma), a process dependent on
CC       Th2 immune response. In the NF-kappa-B-mediated inflammatory
CC       response, can relieve SETD6-dependent repression of NF-kappa-B
CC       target genes by phosphorylating the RELA subunit at 'Ser-311'.
CC       Necessary and sufficient for LTP maintenance in hippocampal CA1
CC       pyramidal cells. In vein endothelial cells treated with the
CC       oxidant peroxynitrite, phosphorylates STK11 leading to nuclear
CC       export of STK11, subsequent inhibition of PI3K/Akt signaling, and
CC       increased apoptosis. Phosphorylates VAMP2 in vitro
CC       (PubMed:17313651). {ECO:0000269|PubMed:11035106,
CC       ECO:0000269|PubMed:12162751, ECO:0000269|PubMed:15084291,
CC       ECO:0000269|PubMed:15324659, ECO:0000269|PubMed:17313651,
CC       ECO:0000269|PubMed:18321849, ECO:0000269|PubMed:9447975}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: Atypical PKCs (PRKCI and PRKCZ) exhibit an
CC       elevated basal enzymatic activity (that may be due to the
CC       interaction with SMG1 or SQSTM1) and are not regulated by
CC       diacylglycerol, phosphatidylserine, phorbol esters or calcium
CC       ions. Two specific sites, Thr-410 (activation loop of the kinase
CC       domain) and Thr-560 (turn motif), need to be phosphorylated for
CC       its full activation. Phosphatidylinositol 3,4,5-trisphosphate
CC       might be a physiological activator (By similarity). {ECO:0000250}.
CC   -!- SUBUNIT: Forms a ternary complex with SQSTM1 and KCNAB2. Forms
CC       another ternary complex with SQSTM1 and GABRR3. Forms a complex
CC       with SQSTM1 and MAP2K5 (By similarity). Interacts with PARD6A,
CC       PARD6B, PARD6G and SQSTM1. Part of a complex with PARD3, PARD6A or
CC       PARD6B or PARD6G and CDC42 or RAC1. Interacts with ADAP1/CENTA1.
CC       Forms a ternary complex composed of SQSTM1 and PAWR. Interacts
CC       directly with SQSTM1 (Probable). Interacts with IKBKB. Interacts
CC       (via the protein kinase domain) with WWC1. Forms a tripartite
CC       complex with WWC1 and DDR1, but predominantly in the absence of
CC       collagen. Component of the Par polarity complex, composed of at
CC       least phosphorylated PRKCZ, PARD3 and TIAM1. Interacts with PDPK1
CC       (via N-terminal region). Interacts with WDFY2 (via WD repeats 1-3)
CC       (PubMed:16792529). Interacts with VAMP2 (PubMed:17313651). Forms a
CC       complex with WDFY2 and VAMP2 (PubMed:17313651).
CC       {ECO:0000250|UniProtKB:P09217, ECO:0000269|PubMed:10356400,
CC       ECO:0000269|PubMed:11260256, ECO:0000269|PubMed:11755531,
CC       ECO:0000269|PubMed:11781095, ECO:0000269|PubMed:12234671,
CC       ECO:0000269|PubMed:12887891, ECO:0000269|PubMed:12893243,
CC       ECO:0000269|PubMed:16792529, ECO:0000269|PubMed:17313651,
CC       ECO:0000269|PubMed:18190796, ECO:0000269|PubMed:20332120,
CC       ECO:0000269|PubMed:9566925, ECO:0000305}.
CC   -!- INTERACTION:
CC       P31749:AKT1; NbExp=2; IntAct=EBI-295351, EBI-296087;
CC       O95999:BCL10; NbExp=3; IntAct=EBI-295351, EBI-958922;
CC       Q07021:C1QBP; NbExp=2; IntAct=EBI-295351, EBI-347528;
CC       Q9Y624:F11R; NbExp=2; IntAct=EBI-295351, EBI-742600;
CC       P08238:HSP90AB1; NbExp=2; IntAct=EBI-295351, EBI-352572;
CC       P14598:NCF1; NbExp=3; IntAct=EBI-295351, EBI-395044;
CC       P49757-1:NUMB; NbExp=4; IntAct=EBI-295351, EBI-7199607;
CC       P16554:numb (xeno); NbExp=2; IntAct=EBI-295351, EBI-429581;
CC       Q9NPB6:PARD6A; NbExp=8; IntAct=EBI-295351, EBI-81876;
CC       Q9BYG5:PARD6B; NbExp=9; IntAct=EBI-295351, EBI-295391;
CC       Q9BYG4:PARD6G; NbExp=3; IntAct=EBI-295351, EBI-295417;
CC       P41743:PRKCI; NbExp=4; IntAct=EBI-295351, EBI-286199;
CC       Q04759:PRKCQ; NbExp=3; IntAct=EBI-295351, EBI-374762;
CC       P40337:VHL; NbExp=3; IntAct=EBI-295351, EBI-301246;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000269|PubMed:17313651,
CC       ECO:0000269|PubMed:9566925}. Endosome
CC       {ECO:0000269|PubMed:9566925}. Cell junction
CC       {ECO:0000269|PubMed:7597083}. Note=In the retina, localizes in the
CC       terminals of the rod bipolar cells. Associates with endosomes.
CC       Presence of KRIT1, CDH5 and RAP1B is required for its localization
CC       to the cell junction. Colocalizes with VAMP2 and WDFY2 in
CC       intracellular vesicles. {ECO:0000269|PubMed:17313651}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1;
CC         IsoId=Q05513-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q05513-2; Sequence=VSP_041904;
CC       Name=3;
CC         IsoId=Q05513-3; Sequence=VSP_046347;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Expressed in brain, and to a lesser extent in
CC       lung, kidney and testis.
CC   -!- DOMAIN: The PB1 domain mediate mutually exclusive interactions
CC       with SQSTM1 and PARD6B. {ECO:0000269|PubMed:12887891}.
CC   -!- DOMAIN: The C1 domain does not bind the diacylglycerol (DAG).
CC       {ECO:0000269|PubMed:12887891}.
CC   -!- PTM: CDH5 is required for its phosphorylation at Thr-410.
CC       Phosphorylated by protein kinase PDPK1; phosphorylation is
CC       inhibited by the apoptotic C-terminal cleavage product of PKN2.
CC       Phosphorylation at Thr-410 by PI3K activates the kinase.
CC       {ECO:0000269|PubMed:11781095, ECO:0000269|PubMed:15314172,
CC       ECO:0000269|PubMed:20332120, ECO:0000269|PubMed:9768361}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. PKC subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAA78813.1; Type=Erroneous initiation; Note=Translation N-terminally extended.; Evidence={ECO:0000305};
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; L14283; AAA36488.1; -; mRNA.
DR   EMBL; BT007082; AAP35745.1; -; mRNA.
DR   EMBL; AK290995; BAF83684.1; -; mRNA.
DR   EMBL; AK294649; BAH11833.1; -; mRNA.
DR   EMBL; AK294782; BAH11883.1; -; mRNA.
DR   EMBL; AL162271; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL391845; CAI15438.1; -; Genomic_DNA.
DR   EMBL; AL590822; CAI15438.1; JOINED; Genomic_DNA.
DR   EMBL; AL645703; CAI15438.1; JOINED; Genomic_DNA.
DR   EMBL; AL645703; CAI21535.1; -; Genomic_DNA.
DR   EMBL; AL391845; CAI21535.1; JOINED; Genomic_DNA.
DR   EMBL; AL590822; CAI21535.1; JOINED; Genomic_DNA.
DR   EMBL; BC008058; AAH08058.1; -; mRNA.
DR   EMBL; BC014270; AAH14270.1; -; mRNA.
DR   EMBL; Z15108; CAA78813.1; ALT_INIT; mRNA.
DR   CCDS; CCDS37.1; -. [Q05513-1]
DR   CCDS; CCDS41229.1; -. [Q05513-2]
DR   CCDS; CCDS55563.1; -. [Q05513-3]
DR   PIR; JN0877; JN0877.
DR   RefSeq; NP_001028753.1; NM_001033581.1. [Q05513-2]
DR   RefSeq; NP_001028754.1; NM_001033582.1. [Q05513-2]
DR   RefSeq; NP_001229803.1; NM_001242874.1. [Q05513-3]
DR   RefSeq; NP_002735.3; NM_002744.4. [Q05513-1]
DR   RefSeq; XP_016857288.1; XM_017001799.1. [Q05513-2]
DR   UniGene; Hs.496255; -.
DR   ProteinModelPortal; Q05513; -.
DR   SMR; Q05513; -.
DR   BioGrid; 111576; 85.
DR   IntAct; Q05513; 36.
DR   MINT; MINT-5004464; -.
DR   STRING; 9606.ENSP00000367830; -.
DR   BindingDB; Q05513; -.
DR   ChEMBL; CHEMBL3438; -.
DR   DrugBank; DB00675; Tamoxifen.
DR   GuidetoPHARMACOLOGY; 1491; -.
DR   iPTMnet; Q05513; -.
DR   PhosphoSitePlus; Q05513; -.
DR   BioMuta; PRKCZ; -.
DR   DMDM; 68067736; -.
DR   EPD; Q05513; -.
DR   MaxQB; Q05513; -.
DR   PaxDb; Q05513; -.
DR   PeptideAtlas; Q05513; -.
DR   PRIDE; Q05513; -.
DR   DNASU; 5590; -.
DR   Ensembl; ENST00000378567; ENSP00000367830; ENSG00000067606. [Q05513-1]
DR   Ensembl; ENST00000400921; ENSP00000383712; ENSG00000067606. [Q05513-2]
DR   Ensembl; ENST00000461106; ENSP00000426412; ENSG00000067606. [Q05513-3]
DR   GeneID; 5590; -.
DR   KEGG; hsa:5590; -.
DR   UCSC; uc001aiq.3; human. [Q05513-1]
DR   CTD; 5590; -.
DR   DisGeNET; 5590; -.
DR   GeneCards; PRKCZ; -.
DR   H-InvDB; HIX0000049; -.
DR   H-InvDB; HIX0029201; -.
DR   HGNC; HGNC:9412; PRKCZ.
DR   HPA; HPA021851; -.
DR   MIM; 176982; gene.
DR   neXtProt; NX_Q05513; -.
DR   OpenTargets; ENSG00000067606; -.
DR   PharmGKB; PA33775; -.
DR   eggNOG; KOG0695; Eukaryota.
DR   eggNOG; ENOG410ZMG2; LUCA.
DR   GeneTree; ENSGT00820000126964; -.
DR   HOGENOM; HOG000233033; -.
DR   HOVERGEN; HBG108317; -.
DR   InParanoid; Q05513; -.
DR   KO; K18952; -.
DR   OMA; RCHVLVP; -.
DR   OrthoDB; EOG091G03Q9; -.
DR   PhylomeDB; Q05513; -.
DR   TreeFam; TF102004; -.
DR   BRENDA; 2.7.11.13; 2681.
DR   Reactome; R-HSA-114604; GPVI-mediated activation cascade.
DR   Reactome; R-HSA-2173791; TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition).
DR   Reactome; R-HSA-5218921; VEGFR2 mediated cell proliferation.
DR   SignaLink; Q05513; -.
DR   SIGNOR; Q05513; -.
DR   ChiTaRS; PRKCZ; human.
DR   GeneWiki; Protein_kinase_M_zeta/Protein_kinase_C_zeta; -.
DR   GenomeRNAi; 5590; -.
DR   PMAP-CutDB; Q05513; -.
DR   PRO; PR:Q05513; -.
DR   Proteomes; UP000005640; Chromosome 1.
DR   Bgee; ENSG00000067606; -.
DR   CleanEx; HS_PRKCZ; -.
DR   ExpressionAtlas; Q05513; baseline and differential.
DR   Genevisible; Q05513; HS.
DR   GO; GO:0045179; C:apical cortex; IEA:Ensembl.
DR   GO; GO:0016324; C:apical plasma membrane; IEA:Ensembl.
DR   GO; GO:0043203; C:axon hillock; IEA:Ensembl.
DR   GO; GO:0005923; C:bicellular tight junction; IEA:Ensembl.
DR   GO; GO:0030054; C:cell junction; TAS:Reactome.
DR   GO; GO:0031252; C:cell leading edge; IEA:Ensembl.
DR   GO; GO:0005911; C:cell-cell junction; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; TAS:ProtInc.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0005768; C:endosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0070062; C:extracellular exosome; IDA:UniProtKB.
DR   GO; GO:0031941; C:filamentous actin; IEA:Ensembl.
DR   GO; GO:0016020; C:membrane; TAS:ProtInc.
DR   GO; GO:0045121; C:membrane raft; IEA:Ensembl.
DR   GO; GO:0005815; C:microtubule organizing center; IEA:Ensembl.
DR   GO; GO:0035748; C:myelin sheath abaxonal region; IEA:Ensembl.
DR   GO; GO:0005635; C:nuclear envelope; IEA:Ensembl.
DR   GO; GO:0016363; C:nuclear matrix; IEA:Ensembl.
DR   GO; GO:0048471; C:perinuclear region of cytoplasm; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:HPA.
DR   GO; GO:0031982; C:vesicle; IDA:UniProtKB.
DR   GO; GO:0071889; F:14-3-3 protein binding; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0043560; F:insulin receptor substrate binding; IC:BHF-UCL.
DR   GO; GO:0046872; F:metal ion binding; IEA:UniProtKB-KW.
DR   GO; GO:0043274; F:phospholipase binding; IEA:Ensembl.
DR   GO; GO:0015459; F:potassium channel regulator activity; IEA:Ensembl.
DR   GO; GO:0019904; F:protein domain specific binding; IEA:Ensembl.
DR   GO; GO:0004672; F:protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0019901; F:protein kinase binding; IEA:Ensembl.
DR   GO; GO:0004697; F:protein kinase C activity; TAS:Reactome.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:BHF-UCL.
DR   GO; GO:0031532; P:actin cytoskeleton reorganization; IEA:Ensembl.
DR   GO; GO:0031584; P:activation of phospholipase D activity; IEA:Ensembl.
DR   GO; GO:0032148; P:activation of protein kinase B activity; IEA:Ensembl.
DR   GO; GO:0016477; P:cell migration; IEA:Ensembl.
DR   GO; GO:0030010; P:establishment of cell polarity; ISS:UniProtKB.
DR   GO; GO:0006954; P:inflammatory response; IEA:UniProtKB-KW.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; IEA:Ensembl.
DR   GO; GO:0007616; P:long-term memory; IEA:Ensembl.
DR   GO; GO:0060291; P:long-term synaptic potentiation; ISS:UniProtKB.
DR   GO; GO:0051899; P:membrane depolarization; IEA:Ensembl.
DR   GO; GO:0060081; P:membrane hyperpolarization; IEA:Ensembl.
DR   GO; GO:0000226; P:microtubule cytoskeleton organization; IEA:Ensembl.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; TAS:ProtInc.
DR   GO; GO:0051346; P:negative regulation of hydrolase activity; IEA:Ensembl.
DR   GO; GO:0046627; P:negative regulation of insulin receptor signaling pathway; IMP:BHF-UCL.
DR   GO; GO:0050732; P:negative regulation of peptidyl-tyrosine phosphorylation; IMP:BHF-UCL.
DR   GO; GO:0031333; P:negative regulation of protein complex assembly; IMP:BHF-UCL.
DR   GO; GO:1990138; P:neuron projection extension; IEA:Ensembl.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell proliferation; IEA:Ensembl.
DR   GO; GO:0001954; P:positive regulation of cell-matrix adhesion; IEA:Ensembl.
DR   GO; GO:0070374; P:positive regulation of ERK1 and ERK2 cascade; IMP:UniProtKB.
DR   GO; GO:2000463; P:positive regulation of excitatory postsynaptic potential; ISS:UniProtKB.
DR   GO; GO:0046326; P:positive regulation of glucose import; IEA:Ensembl.
DR   GO; GO:0046628; P:positive regulation of insulin receptor signaling pathway; ISS:UniProtKB.
DR   GO; GO:2001181; P:positive regulation of interleukin-10 secretion; ISS:UniProtKB.
DR   GO; GO:2000667; P:positive regulation of interleukin-13 secretion; ISS:UniProtKB.
DR   GO; GO:0032753; P:positive regulation of interleukin-4 production; ISS:UniProtKB.
DR   GO; GO:2000664; P:positive regulation of interleukin-5 secretion; ISS:UniProtKB.
DR   GO; GO:0051092; P:positive regulation of NF-kappaB transcription factor activity; ISS:UniProtKB.
DR   GO; GO:2000553; P:positive regulation of T-helper 2 cell cytokine production; ISS:UniProtKB.
DR   GO; GO:0045630; P:positive regulation of T-helper 2 cell differentiation; ISS:UniProtKB.
DR   GO; GO:0051291; P:protein heterooligomerization; IEA:Ensembl.
DR   GO; GO:0070528; P:protein kinase C signaling; IEA:Ensembl.
DR   GO; GO:0072659; P:protein localization to plasma membrane; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0007179; P:transforming growth factor beta receptor signaling pathway; TAS:Reactome.
DR   GO; GO:0047496; P:vesicle transport along microtubule; IEA:Ensembl.
DR   CDD; cd00029; C1; 1.
DR   CDD; cd05617; STKc_aPKC_zeta; 1.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR034662; aPKC_zeta.
DR   InterPro; IPR020454; DAG/PE-bd.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR000270; PB1_dom.
DR   InterPro; IPR002219; PE/DAG-bd.
DR   InterPro; IPR012233; PKC.
DR   InterPro; IPR017892; Pkinase_C.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00130; C1_1; 1.
DR   Pfam; PF00564; PB1; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   Pfam; PF00433; Pkinase_C; 1.
DR   PIRSF; PIRSF000554; PKC_zeta; 1.
DR   PRINTS; PR00008; DAGPEDOMAIN.
DR   SMART; SM00109; C1; 1.
DR   SMART; SM00666; PB1; 1.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS51745; PB1; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
DR   PROSITE; PS00479; ZF_DAG_PE_1; 1.
DR   PROSITE; PS50081; ZF_DAG_PE_2; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; ATP-binding; Cell junction; Complete proteome;
KW   Cytoplasm; Endosome; Inflammatory response; Kinase; Metal-binding;
KW   Nucleotide-binding; Phosphoprotein; Polymorphism; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Zinc; Zinc-finger.
FT   CHAIN         1    592       Protein kinase C zeta type.
FT                                /FTId=PRO_0000055701.
FT   DOMAIN       15     98       PB1. {ECO:0000255|PROSITE-
FT                                ProRule:PRU01081}.
FT   DOMAIN      252    518       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      519    590       AGC-kinase C-terminal.
FT   ZN_FING     130    180       Phorbol-ester/DAG-type.
FT                                {ECO:0000255|PROSITE-ProRule:PRU00226}.
FT   NP_BIND     258    266       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION       79    145       Interaction with SQSTM1. {ECO:0000250}.
FT   ACT_SITE    376    376       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     281    281       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     410    410       Phosphothreonine; by PDPK1 and PI3K.
FT                                {ECO:0000269|PubMed:15314172,
FT                                ECO:0000269|PubMed:20332120,
FT                                ECO:0000269|PubMed:9768361}.
FT   MOD_RES     560    560       Phosphothreonine.
FT                                {ECO:0000244|PubMed:18669648,
FT                                ECO:0000244|PubMed:24275569}.
FT   MOD_RES     591    591       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P09217}.
FT   VAR_SEQ       1    183       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_041904.
FT   VAR_SEQ       1    112       MPSRTGPKMEGSGGRVRLKAHYGGDIFITSVDAATTFEELC
FT                                EEVRDMCRLHQQHPLTLKWVDSEGDPCTVSSQMELEEAFRL
FT                                ARQCRDEGLIIHVFPSTPEQPGLPCPGEDK -> MLTPRTD
FT                                E (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_046347.
FT   VARIANT      49     49       R -> H (in dbSNP:rs35271800).
FT                                /FTId=VAR_050560.
FT   VARIANT      84     84       R -> H (in dbSNP:rs56017162).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042310.
FT   VARIANT     514    514       S -> F (in a colorectal cancer sample;
FT                                somatic mutation).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035467.
FT   VARIANT     519    519       R -> C (in a colorectal adenocarcinoma
FT                                sample; somatic mutation;
FT                                dbSNP:rs376894109).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_042311.
FT   MUTAGEN      19     19       K->A: No effect on interaction with
FT                                SQSTM1 and PARD6B.
FT                                {ECO:0000269|PubMed:12887891}.
FT   MUTAGEN      62     62       D->A: Loss of interaction with SQSTM1 and
FT                                PARD6B. {ECO:0000269|PubMed:12887891}.
FT   MUTAGEN      66     66       D->A: Loss of interaction with SQSTM1 and
FT                                PARD6B. {ECO:0000269|PubMed:12887891}.
FT   CONFLICT      6      6       G -> D (in Ref. 1; AAA36488).
FT                                {ECO:0000305}.
FT   CONFLICT    198    198       K -> R (in Ref. 3; BAF83684).
FT                                {ECO:0000305}.
FT   CONFLICT    262    262       S -> T (in Ref. 1; AAA36488).
FT                                {ECO:0000305}.
FT   CONFLICT    281    281       K -> R (in Ref. 3; BAH11883).
FT                                {ECO:0000305}.
FT   CONFLICT    366    366       F -> L (in Ref. 3; BAF83684).
FT                                {ECO:0000305}.
FT   CONFLICT    500    500       R -> G (in Ref. 3; BAF83684).
FT                                {ECO:0000305}.
FT   CONFLICT    522    522       D -> G (in Ref. 3; BAF83684).
FT                                {ECO:0000305}.
SQ   SEQUENCE   592 AA;  67660 MW;  88CCD0577E6A596C CRC64;
     MPSRTGPKME GSGGRVRLKA HYGGDIFITS VDAATTFEEL CEEVRDMCRL HQQHPLTLKW
     VDSEGDPCTV SSQMELEEAF RLARQCRDEG LIIHVFPSTP EQPGLPCPGE DKSIYRRGAR
     RWRKLYRANG HLFQAKRFNR RAYCGQCSER IWGLARQGYR CINCKLLVHK RCHGLVPLTC
     RKHMDSVMPS QEPPVDDKNE DADLPSEETD GIAYISSSRK HDSIKDDSED LKPVIDGMDG
     IKISQGLGLQ DFDLIRVIGR GSYAKVLLVR LKKNDQIYAM KVVKKELVHD DEDIDWVQTE
     KHVFEQASSN PFLVGLHSCF QTTSRLFLVI EYVNGGDLMF HMQRQRKLPE EHARFYAAEI
     CIALNFLHER GIIYRDLKLD NVLLDADGHI KLTDYGMCKE GLGPGDTTST FCGTPNYIAP
     EILRGEEYGF SVDWWALGVL MFEMMAGRSP FDIITDNPDM NTEDYLFQVI LEKPIRIPRF
     LSVKASHVLK GFLNKDPKER LGCRPQTGFS DIKSHAFFRS IDWDLLEKKQ ALPPFQPQIT
     DDYGLDNFDT QFTSEPVQLT PDDEDAIKRI DQSEFEGFEY INPLLLSTEE SV
//
